Role and Redirection of IgE against Cancer

Antibodies

Elisa A. Nigro¹  Antonio G. Siccardi¹ 

[1] Molecular Immunology Group, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy; E-Mails:

关键词: IgE;    FcεRI;    CD23;    ADCC;    cancer;    immunotherapy;   

DOI  :  10.3390/antib2020371

来源: mdpi

【 摘 要 】

IgE is a highly elusive antibody class, yet a tremendously powerful elicitor of immune reactions. Despite huge efforts spent on the characterization and understanding of the IgE system many questions remain either unanswered or only marginally addressed. One above all relates to the role of IgE. A common doubt is based on whether IgE mode of action should only be relegated to anti-parasite immunity and allergic manifestations. In search for a hidden role of IgE, reports from several laboratories are described herein in which a natural IgE link to cancer or the experimental redirection of IgE against cancer have been investigated. Epidemiological and investigational studies are trying to elucidate a possible direct intervention of endogenous IgE against cancer, raising thus far no definitive evidence. Conversely, experimental approaches implementing several strategies and engineered IgE formats built up a series of convincing results indicating that cancer might be tackled by the effector functions of this immunoglobulin class. Because of its peculiar immune features, IgE may present a superior anti-tumor performance as compared to IgG. However, extreme care should be taken on how IgE-based anti-tumor approaches should be devised. Overall, IgE appears as a promising resource, likely destined to enrich the anti-cancer arsenal.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.